Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
85 Cards in this Set
- Front
- Back
What are the manifestations of alzheimer's disease?
|
loss of cognitive function, memory deterioration, impairment in activities of daily living, neuropsychiatric symptoms, behavior issues
|
|
Define dementia
|
Any 2:
-difficulties learning/retaining new information -impairment in completing complex tasks and reasoning abilities -impairment in visuspatial function and geographic orientation -language difficulties |
|
What does impairment in episodic declarative memory mean?
|
difficulties in learning/retaining new information
|
|
What does impairment in executive cognitive functions mean?
|
impairment in completing complex tasks and reasoning abilities
|
|
What is the pathophysiology in AD?
|
senile plaques (beta amyloid and amyloid precursor protein) and neurotibrillary tangles (tau)
|
|
What is the cholinergic hypothesis of AD?
|
cognitive deterioration due to loss of cns acetylcholine
|
|
What are the epidemiologic risk factors for AD?
|
age, female sex, head trauma, midlife hypertension, stroke, small head circumference
|
|
What are the genetic risk factors for AD?
|
ApoE-e4 genotype, SORL1 genotype, family hx of dementia
|
|
What are the physiologic risk factors for AD?
|
hypothyroidism, high cholesterol, diabetes, low diastolic BP, increased homocysteine levels
|
|
Secondary causes of dementia?
|
CNS drugs, systemic metabolic disorders, endocrine disorders, neoplasms, subdural hematomas, normal pressure hydrocephalus, meningitis
|
|
What are the causes of primary dementias?
|
alzheimers, vascular dementia, dementia with lewy bodies, frontotemporal lobar degenerations, Creutzfeldt Jakob disease
|
|
What are the s/sx of Creutzfeldt Jakob disease?
|
rapid onset, neurological signs, abnormal CSF or MR
|
|
What are the s/sx of frontotemporal lobar degeneration?
|
aphasia or disorder of behavior, comportment or executive function
|
|
What are the s/sx of dementia with lewy bodies?
|
extrapyramadial signs, hallucinations, sleep disorders
|
|
What are the s/sx of vascular dementia?
|
cognitive impairment related to stroke or infarcts on imaging
|
|
Core diagnostic features that are included in episodic memory impairment of AD pts early on?
|
-memory loss over more than 6 months
-significantly impaired episodic memory on objective testing |
|
Supportive diag features in AD?
|
-medial temporal lobe atrophy
-CSF biomarker -PET imaging -AD genotyping (autosomal dominant) in immediate family member |
|
Drugs that can impair cognitive function in AD pts?
|
BAAMC - barbiturates, anticholinergics, antispasmodics, muscle relaxants, cns stimulants
|
|
antidepressant anticholinergic to avoid in AD pts?
|
amitriptylline
|
|
antiarrhytmic anticholinergic to avoid in AD pts?
|
quinidine, disopyramide
|
|
antiemetic anticholinergic to avoid in AD pts?
|
diphenhydrinate, meclizine, promethazine
|
|
typical and atypical antipsychotics anticholinergic to avoid in AD pts?
|
chlopromazine, clozapine, olazapine, quetiapine
|
|
bronchodilators anticholinergic to avoid in AD pts?
|
ipratropium
|
|
gi antispasmotics anticholinergic to avoid in AD pts?
|
hyoscyamine
|
|
mydiatics/cycloplegics anticholinergic to avoid in AD pts?
|
atropine, cyclopentolate
|
|
overactive bladder rx anticholinergic to avoid in AD pts?
|
oxybutynin
|
|
parkinson's rx anticholinergic to avoid in AD pts?
|
bentropine
|
|
skeletal muscle relaxant anticholinergic to avoid in AD pts?
|
cyclobenzaprine
|
|
Tx goal in AD?
|
-temporarily improve, stabilize or slow the decline of cognitive functional, and behavioral symptoms
-reduce caregiver burden and delay nursing home placement |
|
MOA of donepezil (aricept)?
|
selective ach inhibitor
|
|
moa of galantamine?
|
selective ach'ase inhibitor and nicotinic receptor modulator
|
|
trade name for galantamine?
|
Razadyne
|
|
moa of rivastigmine?
|
dual ach'ase and butyrylcholinesterase inhibitor
|
|
trade name of rivastigmine?
|
exelon
|
|
Clinical benefits of cholinesterase inhibitors?
|
improved or delayed decline in cognition, preserved functional ability, improved disturbed behaviors, reduce caregiver burden, delayed nursing home placement
|
|
SEs of donepezil?
|
N/V, diarrhea, anorexia, insomnia, muscle cramps, fatigue, syncope
|
|
SEs of rivastigmine?
|
N/V, anorexia, weight loss, dyspepsia, asthenia, dizziness, fatigue, diarrhea
|
|
SEs of galantamine?
|
N/V, anorexia, weight loss, syncope, fatigue, dizziness, dyspepsia, diarrhea
|
|
MOA of memantine?
|
non-competitive n-methyl-D-aspartate (NMDA) antagonist
|
|
What is the trade name for memantine?
|
namenda
|
|
Clinical benefits of memantine?
|
memantine added to donepezil in moderate to severe AD resulted in significantly better outcomes than donepezil plus placebo over 6 months
|
|
adverse effects of memantine?
|
confusion, somnolence, falls, HA
|
|
initial dose for donepezil?
|
5mg/day
|
|
target dose for donepezil?
|
10mg/day
|
|
initial dose for galantamine?
|
8mg/day
|
|
target dose for galantamine?
|
16-24mg/day
|
|
initial dose for rivastigmine?
|
3mg/day
|
|
target dose for rivastigmine?
|
6-12mg/day
|
|
initial dose for memantine?
|
5mg/day
|
|
target dose for memantine?
|
20mg/day
|
|
CYP metabolism for donepezil
|
2d6 & 3a4
|
|
CYP metabolism for galantamine?
|
2d6 & 3a4
|
|
CYP metabolism for rivastigmine?
|
no
|
|
CYP metabolism for memantine?
|
no
|
|
doses per day for donepezil?
|
one
|
|
doses per day for galantamine?
|
two (imm), one (ER)
|
|
doses per day for rivastigmine?
|
two
|
|
doses per day for memantine?
|
two (1st wk is one/d)
|
|
time to change dose for donepezil?
|
q 4-6wks
|
|
time to change dose for galantamine?
|
q4 wks to target dose or SEs
|
|
time to change dose for rivastigmine?
|
q 2 wks to target or SEs
|
|
time to change dose for memantine?
|
q wk to target or SEs
|
|
Therapy for use in vascular dementia?
|
possibly cholinesterase inhibitors or memantine. Importance is to get early tx of HTN and vascular disease
|
|
Therapy for use in dementia with lewy bodies?
|
cholinesterase inhibitors in mild-to-moderate disease
|
|
Therapy for use in dementia of parkinson's disease?
|
cholinesterase inhibiotrs (only to use rivastigmine) in mild-to-moderate
|
|
Is intended to improve our ability to rapidly deploy light, lean and lethal elements of air and space forces anywhere on the globe, while providing predictibility and stability for all airmen, To meet this challenge, the Air Force assigned people and equipment from active duty, Air National Guard and Air Force Reserve units into 10 Air and Space expeditionary forces, two crisis-response air and space expeditionary wings and five lead mobility wings.
|
EAF
|
|
Treatment failure washout period length?
|
no washout period
|
|
AEs to donepezil washout period?
|
1-2 wks
|
|
AEs to rivastigmine or galantamine washout period?
|
1 day
|
|
MOA of secretase modulators?
|
decrease beta amyloid production
|
|
name of secretase modulator discussed?
|
bryostatin-1
|
|
name of vaccine for beta amyloid?
|
vaccine AN1792
|
|
name of beta amyloid fibrilization inhibitors?
|
NC-531 (alzhemed), PBT-1 (Clioquinol), PBT-2
|
|
name of anti-tau medications?
|
CDK5, GSK-3B
|
|
Purpose of mini-mental exam?
|
measures cognition
|
|
what does the mini-mental assess?
|
orientation, registration, recall, language, and attention (for medical personel to use)
|
|
On average, how much does the mini-mental score decrease per year in pts with AD?
|
2-4 pts
|
|
what is the purpose of the function activities questionnaire?
|
intended to quantify level of disability (for caregivers to use)
|
|
what is the purpose of the neuropsychiatric inventory?
|
measures disturbed behaviors
|
|
what does neuropsychiatric inventory assess?
|
frequency and severity of 12 symptoms (agitation, irritability, depression, hallucinations, etc)
|
|
MMSE score of 30?
|
no dementia
|
|
MMSE score of 26-29?
|
questionable dementia
|
|
MMSE score of 21-25?
|
mild dementia
|
|
MMSE score of 11-20?
|
moderate dementia?
|
|
MMSE of 0-10?
|
severe dementia
|